Insmed sees FY23 ARIKAYCE revenue $305.2M, consensus $302.75M

Based on preliminary unaudited financial information, the company expects total global net product sales of ARIKAYCE to be approximately $305.2M for the full year 2023, with net sales across the United States, Japan, and Europe as follows. This represents 24% year-over-year growth from the full year 2022, including growth in the U.S. of 21% and in Japan of 16%. Insmed anticipates 2024 global ARIKAYCE revenues to be between $340M-$360M, representing 15% year-over-year growth at the midpoint compared to 2023. FY24 revenue consensus $361.63M. “The year ahead will mark the most transformational period in Insmed’s history as we strive to become the next great biotechnology company,” said Will Lewis, Chair and CEO of Insmed. “From the readout of our highly anticipated Phase 3 ASPEN study, to our first Phase 2 topline TPIP data, to the advancement of our ARIKAYCE label expansion program, 2024 is the moment we have been waiting for. Each of these three programs, if successful, has the potential to achieve peak sales of more than $1 billion. Over the next 12 months, we have the opportunity to truly break out from the pack, delivering tangible results for our shareholders, while, more importantly, making a meaningful impact in the lives of patients with serious and rare diseases.” .